Lupin Secures European Rights for Presbyopia Drug YUVEZZI

Lupin Limited's European subsidiary, VISUfarma B.V., will pay up to €75 million for exclusive rights to commercialize YUVEZZI™ in the EU, UK, Switzerland, Norway, and Iceland.

Reader Takeaway: Expands specialty business; YUVEZZI faces competition in presbyopia market.

What just happened

Lupin Limited, through its wholly owned Dutch subsidiary VISUfarma B.V., has entered into an exclusive license agreement with U.S.-based Visus Therapeutics, Inc. This deal grants VISUfarma the rights to commercialize YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) across the European Union, the United Kingdom, Switzerland, Norway, and Iceland. The agreement covers all aspects of commercialization, including regulatory activities, marketing, promotion, distribution, and sales.

Why this matters

This strategic move is aimed at significantly strengthening Lupin's ophthalmology portfolio and expanding its Specialty Business segment. The addition of YUVEZZI™ is expected to create long-term growth opportunities, particularly in the burgeoning presbyopia treatment market within the specified European territories.

The backstory

Lupin has been actively building its presence in the ophthalmology space. YUVEZZI™ is a once-daily eye drop approved by the U.S. FDA for treating presbyopia in adults. It combines carbachol and brimonidine tartrate to temporarily improve near vision by constricting pupils. This partnership allows Lupin to leverage an approved product in key international markets.

What changes now

VISUfarma B.V. will now be responsible for obtaining regulatory approvals, marketing, distributing, and selling YUVEZZI™ in the agreed-upon European regions. This involves managing the product lifecycle and commercial strategy for YUVEZZI™ in these territories.

Risks to watch

While YUVEZZI™ has FDA approval, its success in Europe will depend on regulatory approvals in those specific countries and market acceptance. The presbyopia treatment market is competitive, and Lupin will face established players and potentially new entrants.

Peer comparison

Companies like Novartis (through its Alcon division), AbbVie (through Allergan), and Johnson & Johnson are major players in the ophthalmology market, offering a range of solutions for various eye conditions, including refractive errors and age-related vision decline.

Context metrics (time-bound)

The agreement includes a total potential consideration of up to €75 million. This comprises an initial €20 million investment via a SAFE instrument and up to €55 million in milestone payments. Additionally, tiered royalty payments and further sales milestone payments are structured based on net sales performance.

What to track next

Investors will be keen to monitor the progress of regulatory submissions in the European territories, the launch timeline for YUVEZZI™, and its subsequent sales performance against the backdrop of the €75 million potential payout and royalty structure.